KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Financing Activities (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Cash from Financing Activities for 16 consecutive years, with $239.5 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 197.2% to $239.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$85.2 million through Dec 2025, up 61.08% year-over-year, with the annual reading at -$85.2 million for FY2025, 61.08% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $239.5 million at Halozyme Therapeutics, up from -$22.4 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $367.8 million in Q2 2022, with the low at -$299.0 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is -$13.6 million, with a median of -$1.9 million recorded in 2024.
  • The sharpest move saw Cash from Financing Activities surged 921.81% in 2022, then tumbled 26480.45% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$156.0 million in 2021, then soared by 104.06% to $6.3 million in 2022, then tumbled by 4048.81% to -$249.9 million in 2023, then grew by 1.4% to -$246.4 million in 2024, then surged by 197.2% to $239.5 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $239.5 million, -$22.4 million, and -$299.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.